BR0314253A - Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama - Google Patents

Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama

Info

Publication number
BR0314253A
BR0314253A BR0314253-1A BR0314253A BR0314253A BR 0314253 A BR0314253 A BR 0314253A BR 0314253 A BR0314253 A BR 0314253A BR 0314253 A BR0314253 A BR 0314253A
Authority
BR
Brazil
Prior art keywords
breast cancer
treatment
dppe
combination
cancer treatment
Prior art date
Application number
BR0314253-1A
Other languages
English (en)
Inventor
Lorne J Brandes
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Publication of BR0314253A publication Critical patent/BR0314253A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UMA COMBINAçãO DE DPPE COM OUTROS AGENTES QUIMIOTERáPICOS PARA O TRATAMENTO DE CâNCER DE MAMA". é fornecido um melhor tratamento adjuvante de câncer de mama estágio I ou II no qual pacientes são administradas com um agente quimioterápico ativo no câncer de mama no qual um composto de difenil que é um potente antagonista de ligação de histamina no receptor intracelular de histamina é inicialmente administrado antes da administração do agente quimioterápico. Espera-se que tal pré-tratamento leve a uma maior sobrevivência total para pacientes que não receberam quimioterapia prévia ou nenhum tipo de tratamento prévio (quimioterapia, radioterapia e/ou tratamento hormonal) ou tumores negativos a receptor de estrogênio.
BR0314253-1A 2002-09-11 2003-09-05 Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama BR0314253A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40958402P 2002-09-11 2002-09-11
PCT/CA2003/001343 WO2004024131A1 (en) 2002-09-11 2003-09-05 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR0314253A true BR0314253A (pt) 2005-07-05

Family

ID=31993981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314253-1A BR0314253A (pt) 2002-09-11 2003-09-05 Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama

Country Status (11)

Country Link
US (1) US20060142287A1 (pt)
EP (1) EP1539123A1 (pt)
JP (1) JP2007523825A (pt)
KR (1) KR20050090366A (pt)
CN (1) CN1703212A (pt)
AU (1) AU2003266049A1 (pt)
BR (1) BR0314253A (pt)
CA (1) CA2497879A1 (pt)
MX (1) MXPA05002720A (pt)
RU (1) RU2005110401A (pt)
WO (1) WO2004024131A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104622880B (zh) * 2015-02-09 2017-05-17 南京医科大学第一附属医院 一种抗肿瘤药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618846A (en) * 1990-12-17 1997-04-08 University Of Manitoba Treatment method for cancer
PL369792A1 (en) * 2001-11-01 2005-05-02 Ym Biosciences, Inc. Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
EP1441711A1 (en) * 2001-11-09 2004-08-04 The University of Manitoba Treatment of breast cancer

Also Published As

Publication number Publication date
KR20050090366A (ko) 2005-09-13
RU2005110401A (ru) 2005-10-10
WO2004024131A1 (en) 2004-03-25
AU2003266049A1 (en) 2004-04-30
JP2007523825A (ja) 2007-08-23
CN1703212A (zh) 2005-11-30
EP1539123A1 (en) 2005-06-15
MXPA05002720A (es) 2005-09-08
US20060142287A1 (en) 2006-06-29
CA2497879A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
AR009757A1 (es) USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO(
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
PE58998A1 (es) Terapia combinada para la osteoporosis
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
BR0215650A (pt) Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica
CA2450942A1 (en) Method of treating hyperproliferative diseases using active vitamin d analogues
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
Conte et al. Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.
CO5271696A1 (es) Procedimiento para reducir la morbilidad y el riesgo de mortalidad
BR0008468A (pt) Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
AR069682A1 (es) Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
DK1526856T3 (da) Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi
UY30175A1 (es) Combinacion farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
WO1997042968A3 (en) Administration of histamine for therapeutic purposes
MXPA04007584A (es) Compuestos de poliamina y composiciones para su uso en conjunto con una terapia contra el cancer.
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
BR0314253A (pt) Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
Bunn Jr et al. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.